AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35627702 — intervention group
Group type: COMPARATOR
Intervention: Written material (Control) (n = 81)
Number of subjects: 458
Study 32430557 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and planning (CEP) intervention
Number of subjects: 0
Study 32430557 — intervention group
Group type: COMPARATOR
Intervention: Resources for services (RS) intervention
Number of subjects: 0
Study 34592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryonia alba 30c
Number of subjects: 2294
Study 34592778 — intervention group
Group type: EXPERIMENTAL
Intervention: CVN01 nosode 30c
Number of subjects: 2294
Study 34592778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2294
Study 34592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenicum album 30c
Number of subjects: 2294
Study 34592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (Arsenicum album 30c, Bryonia alba 30c, Gelsemium sempervirens 30c, and Influenzinum 30c)
Number of subjects: 2294
Study 34592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Camphora 1M
Number of subjects: 2294
Study 34139801 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical remission of Cushing syndrome
Number of subjects: 0
Study 34139801 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0
Study 34139801 — intervention group
Group type: COMPARATOR
Intervention: Age and sex matched control persons
Number of subjects: 0
Study 32514196 — intervention group
Group type: EXPERIMENTAL
Intervention: Short treatment regimen (9 to 11 months)
Number of subjects: 0
Study 32514196 — intervention group
Group type: COMPARATOR
Intervention: Long treatment regimen (20 to 22 months)
Number of subjects: 0
Study 32400032 — intervention group
Group type: EXPERIMENTAL
Intervention: SIALAC breastfeeding self-efficacy promoting programme
Number of subjects: 112
Study 32400032 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 112
Study 32901299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 60
Study 32901299 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 60
Study 35397508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 73
Study 35397508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 34706653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid cash card incentive
Number of subjects: 420
Study 34706653 — intervention group
Group type: COMPARATOR
Intervention: Postpaid cash card incentive
Number of subjects: 420
Study 35041809 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CBLH (single injection)
Number of subjects: 72
Study 35041809 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CBLH (single injection)
Number of subjects: 72
Study 35041809 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% CBLH (single injection)
Number of subjects: 72
Study 35041809 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CBLH (4-time injections)
Number of subjects: 72
Study 35041809 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CBLH (4-time injections)
Number of subjects: 72
Study 35041809 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% CBLH (4-time injections)
Number of subjects: 72
Study 35041809 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (1 injection)
Number of subjects: 72
Study 35041809 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (4 injections)
Number of subjects: 72
Study 33172449 — intervention group
Group type: EXPERIMENTAL
Intervention: FDI criteria
Number of subjects: 0
Study 33172449 — intervention group
Group type: COMPARATOR
Intervention: ICCMS criteria
Number of subjects: 0
Study 33651729 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 118
Study 33651729 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension Training (ST)
Number of subjects: 118
Study 33651729 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 118
Study 33119068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3AV (10 μg)
Number of subjects: 0
Study 33119068 — intervention group
Group type: COMPARATOR
Intervention: 1AV (20 µg)
Number of subjects: 0
Study 33119068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3AV
Number of subjects: 0
Study 33119068 — intervention group
Group type: COMPARATOR
Intervention: 1AV
Number of subjects: 0
Study 33119068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3AV and 1AV
Number of subjects: 0
Study 32089064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/day plus prenatal vitamins containing 400 IU vitamin D3)
Number of subjects: 92
Study 32089064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 33779410 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteus maximus tenotomy (group 1)
Number of subjects: 158
Study 33779410 — intervention group
Group type: COMPARATOR
Intervention: No gluteus maximus tenotomy (group 2)
Number of subjects: 158
Study 32138782 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management group
Number of subjects: 24
Study 32138782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 34098984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine, full course delivered by trained village health workers to all residents of compounds with reported clinical cases.
Number of subjects: 3738
Study 34098984 — intervention group
Group type: COMPARATOR
Intervention: Control group screened for infection at the time of index case reporting, treated according to national guidelines.
Number of subjects: 3738
Study 34098984 — intervention group
Group type: COMPARATOR
Intervention: Intervention arm (dihydroartemisinin-piperaquine) vs Control arm (screening and treatment).
Number of subjects: 3738
Study 32895281 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (target Hb levels of 70-90 g/L)
Number of subjects: 0
Study 32895281 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (target Hb levels of 100-120 g/L)
Number of subjects: 0
Study 32895281 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study 35481441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at 4.9 µg/kg
Number of subjects: 5
Study 35481441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at 8.4 µg/kg
Number of subjects: 5
Study 35481441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at 11.8 µg/kg
Number of subjects: 5
Study 35481441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at approximately 5.0 µg/kg
Number of subjects: 5
Study 35481441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at approximately 11.8 µg/kg
Number of subjects: 5
Study 35347400 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate spa therapy
Number of subjects: 128
Study 35347400 — intervention group
Group type: COMPARATOR
Intervention: Usual treatments (Control)
Number of subjects: 128
Study 32534949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Calorie Control guided by indirect calorimetry
Number of subjects: 417
Study 32534949 — intervention group
Group type: COMPARATOR
Intervention: Standard calorie administration based on predictive equations (20-25 kcal/kg ideal body weight/day)
Number of subjects: 417
Study 32095935 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training + green tea extract supplementation (ET + GTE)
Number of subjects: 45
Study 32095935 — intervention group
Group type: COMPARATOR
Intervention: Endurance training + placebo (ET + P)
Number of subjects: 45
Study 32095935 — intervention group
Group type: COMPARATOR
Intervention: No endurance training + placebo (P)
Number of subjects: 45
Study 34017343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1790GAHB vaccine (1.5/25 µg OAg/protein)
Number of subjects: 0
Study 34017343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1790GAHB vaccine (0.06/1, 0.3/5, 1.5/25, 3/50, 6/100 µg OAg/protein)
Number of subjects: 0
Study 34017343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36278294 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-P1 45 mg
Number of subjects: 3
Study 36278294 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-033P 90 mg
Number of subjects: 3
Study 36278294 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-043P 90 mg
Number of subjects: 3
Study 33368696 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-point risk score incorporating mechanical ventilation, serum bilirubin, serum creatinine, and donor age
Number of subjects: 1156
Study 33368696 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scores above 3 points
Number of subjects: 1156
Study 33583253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (MIX)
Number of subjects: 64
Study 33583253 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality balance training (VR)
Number of subjects: 64
Study 33583253 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional balance training (BT)
Number of subjects: 64
Study 33583253 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CON)
Number of subjects: 64
Study 34973935 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH administered at 20:00 h
Number of subjects: 105
Study 34973935 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist administered at 08:00 h
Number of subjects: 105
Study 34086608 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with limited deep sclerectomy (LDS)
Number of subjects: 68
Study 34086608 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone
Number of subjects: 68
Study 32940642 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/L of α-MSH treatment
Number of subjects: 16
Study 32940642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 35714103 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Support for Progress (PSP)
Number of subjects: 0
Study 35714103 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 32286232 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month internet-based intervention group (n=55)
Number of subjects: 105
Study 32286232 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=50)
Number of subjects: 105
Study 36468983 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI-Duloxetine therapy at a dose of 60 mg per day for 8 weeks
Number of subjects: 61
Study 36468983 — intervention group
Group type: COMPARATOR
Intervention: Trimebutine therapy at a dose of 600 mg per day
Number of subjects: 61
Study 34619162 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TSST
Number of subjects: 68
Study 34619162 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-TSST
Number of subjects: 68
Study 34619162 — intervention group
Group type: COMPARATOR
Intervention: Placebo TSST
Number of subjects: 68
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampled mouth-rinsing fluid (saliva sampling [SAL] with pooled PCR) plus nasal rapid antigen self-test (RAgT) (group 1)
Number of subjects: 452
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampled mouth-rinsing fluid (SAL) only (group 2)
Number of subjects: 452
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal rapid antigen self-test (RAgT) only (group 3)
Number of subjects: 452
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation rates
Number of subjects: 452
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 PCR tests
Number of subjects: 452
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly participation rates
Number of subjects: 452
Study 36107424 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of SARS-CoV-2 introduction into DCC
Number of subjects: 452
Study 33677193 — intervention group
Group type: EXPERIMENTAL
Intervention: MO (optimized original map)
Number of subjects: 30
Study 33677193 — intervention group
Group type: COMPARATOR
Intervention: MC- (map minus C)
Number of subjects: 30
Study 33677193 — intervention group
Group type: COMPARATOR
Intervention: MT- (map minus T)
Number of subjects: 30
Study 33677193 — intervention group
Group type: COMPARATOR
Intervention: MT+ (map plus T)
Number of subjects: 30
Study 32479140 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 0
Study 32479140 — intervention group
Group type: COMPARATOR
Intervention: secukinumab
Number of subjects: 0
Study 34784820 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 266
Study 34784820 — intervention group
Group type: COMPARATOR
Intervention: Control (Physical Education classes)
Number of subjects: 266
Study 34087225 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMOS intervention (multicomponent intervention including staff training in communication, pain treatment, medication review, organization of activities, and safety) for 4 months
Number of subjects: 723
Study 34087225 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 723
Study 34087225 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMOS intervention
Number of subjects: 723
Study 36357536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritualized action
Number of subjects: 268
Study 36357536 — intervention group
Group type: COMPARATOR
Intervention: Control action
Number of subjects: 268
Study 36357536 — intervention group
Group type: COMPARATOR
Intervention: Neutral (no-activity)
Number of subjects: 268
Study 33081825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 300
Study 33081825 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 300
Study 35793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation
Number of subjects: 0
Study 35793927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34376321 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation
Number of subjects: 24
Study 34376321 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 24
Study 36438274 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour indoor clubbing event with no masks, no social distance, maximum room capacity, and ventilation
Number of subjects: 4400
Study 36438274 — intervention group
Group type: COMPARATOR
Intervention: Control group asked not to go to the club
Number of subjects: 4400
Study 33846151 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation plus graduated compression stockings (European class II, 23‐32 mm Hg compression) worn for a median of 18 months
Number of subjects: 0
Study 33846151 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation (standard of care)
Number of subjects: 0
Study 36072909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture therapy
Number of subjects: 0
Study 36072909 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 0
Study 33652910 — intervention group
Group type: EXPERIMENTAL
Intervention: dGTE+ (400 mg·d‐1 EGCG, 50 mg·d‐1 quercetin, 150 mg·d‐1 α-lipoic acid)
Number of subjects: 27
Study 33652910 — intervention group
Group type: EXPERIMENTAL
Intervention: dGTE+
Number of subjects: 27
Study 33652910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 34668304 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM titanium abutments bonded onto titanium bases (Ti-Base)
Number of subjects: 24
Study 34668304 — intervention group
Group type: COMPARATOR
Intervention: Individualized one-piece CAD/CAM titanium abutments
Number of subjects: 24
Study 34668304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 24
Study 37409838 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg kg ‐1 bolus followed by 4 mg kg ‐1 h ‐1 infusion)
Number of subjects: 64
Study 37409838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg kg ‐1 followed by 2 µg kg ‐1 h‐1 infusion)
Number of subjects: 64
Study 33568005 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 25 mg and solifenacin 5–10 mg
Number of subjects: 100
Study 33568005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33252951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban intervention
Number of subjects: 91
Study 35168636 — intervention group
Group type: EXPERIMENTAL
Intervention: Date palm capsule
Number of subjects: 0
Study 35168636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33592211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided management
Number of subjects: 221
Study 33592211 — intervention group
Group type: COMPARATOR
Intervention: Non-ultrasound-guided management
Number of subjects: 221
Study 32976523 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine infusion (28mg/kg) with Intralipid (20%, 90mL/h)
Number of subjects: 8
Study 32976523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (20%, 90mL/h)
Number of subjects: 8
Study 32976523 — intervention group
Group type: COMPARATOR
Intervention: Saline (CON)
Number of subjects: 8
Study 34173051 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Convolutional Neural Network (CNN) model (YOLO) for diagnosing interproximal caries lesions
Number of subjects: 1000
Study 34376533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (first-line)
Number of subjects: 265
Study 34376533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (second-line)
Number of subjects: 265
Study 34376533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (first-line, primary resistance to ET)
Number of subjects: 265
Study 34376533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (first-line, visceral disease)
Number of subjects: 265
Study 34376533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (second-line, visceral disease)
Number of subjects: 265
Study 34376533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (both subgroups)
Number of subjects: 265
Study 34376533 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (first-line)
Number of subjects: 265
Study 34376533 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (second-line)
Number of subjects: 265
Study 35640636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
Number of subjects: 587
Study 34664662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 0
Study 34664662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 18 mg/day
Number of subjects: 0
Study 33002283 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm Q-switched Nd: YAG laser and 4% hydroquinone cream
Number of subjects: 21
Study 33002283 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream alone
Number of subjects: 21
Study 33002283 — intervention group
Group type: EXPERIMENTAL
Intervention: 585-nm Q-switched Nd: YAG laser
Number of subjects: 21
Study 33002283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 21
Study 35218685 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthwash with payayor (Clinacanthus nutans Lindau)
Number of subjects: 120
Study 35218685 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthwash with fingerroot (Boesenbergia rotunda)
Number of subjects: 120
Study 35218685 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with sodium bicarbonate (control)
Number of subjects: 120
Study 34833666 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-assisted cycling
Number of subjects: 39
Study 34833666 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional cycling (VOL)
Number of subjects: 39
Study 34833666 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (CON)
Number of subjects: 39
Study 32403115 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate iron therapy
Number of subjects: 239
Study 32403115 — intervention group
Group type: COMPARATOR
Intervention: Delayed iron therapy (28-day delay)
Number of subjects: 239
Study 35470195 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manual therapy
Number of subjects: 0
Study 35470195 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid nerve root injections
Number of subjects: 0
Study 33495294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 163
Study 33495294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 32940092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with natural orifice specimen extraction (NOSE)
Number of subjects: 92
Study 32940092 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopy
Number of subjects: 92
Study 35226756 — intervention group
Group type: EXPERIMENTAL
Intervention: solution-focused psychotherapy (n=97)
Number of subjects: 326
Study 35226756 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term psychodynamic psychotherapy (n=101)
Number of subjects: 326
Study 35226756 — intervention group
Group type: COMPARATOR
Intervention: long-term psychodynamic psychotherapy (n=128)
Number of subjects: 326
Study 32015285 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 190
Study 32015285 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis
Number of subjects: 190
Study 32015285 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight anastomosis
Number of subjects: 190
Study 32015285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleveland Clinic Colorectal Cancer Quality of Life Questionnaire
Number of subjects: 190
Study 35072639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar intervention video (3.42 minutes long)
Number of subjects: 4013
Study 32853740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 100